Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jacobio Pharmaceuticals has announced the successful administration of the first patient dosage in a Phase III clinical trial of its lung cancer treatment, combining Glecirasib and SHP2 inhibitor JAB-3312, with promising preliminary results. The treatment has shown a high confirmed objective response rate and manageable safety profile, advancing Jacobio’s commitment to providing innovative healthcare solutions. However, the company cautions that the success of the drug’s development and market launch is not yet assured.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.